Kalaris Therapeutics Inc
KLRSLatest QuantConomy context for KLRS: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.
Kalaris Therapeutics Inc
QuantConomy has a structured record for KLRS. More descriptive asset metadata will appear here when the platform record includes it.
- Symbol
- KLRS
- Name
- Kalaris Therapeutics Inc
- Coverage
- 3 market/data records
- Sources
- alphavantage alpaca fmp nasdaq
Recent signals for KLRS
Scored rows are pulled from the same signal API used by the digests.
| Signal | Direction | Score | Observed | Reason |
|---|---|---|---|---|
| corporate event executive change | neutral | 75 | Jul 6, 08:15 PM | KLRS filed 8-K: Director or Officer Changes - 1 material event - [strong neutral signal] |
| earnings earnings release | neutral | 40 | Mar 17, 12:00 AM | KLRS filed an earnings release (8-K Item 2.02 - Results of Operations and Financial Condition) on 2026-03-17. Release-event signal only: confirms results were published, not the figures vs. estimates (no surprise/guidance read). |
| earnings earnings release | neutral | 40 | May 12, 12:00 AM | KLRS filed an earnings release (8-K Item 2.02 - Results of Operations and Financial Condition) on 2026-05-12. Release-event signal only: confirms results were published, not the figures vs. estimates (no surprise/guidance read). |
EARNINGS signals are experimental: currently limited to neutral pre-earnings calendar awareness (no transcript analysis).
Market coverage
| Market | Exchange | Source | Asset record |
|---|---|---|---|
| KLRS | NASDAQ | alphavantage | Kalaris Therapeutics Inc |
| KLRS | NASDAQ | alpaca | Kalaris Therapeutics, Inc. Common Stock |
| KLRS | NASDAQ | fmp | Kalaris Therapeutics Inc |
Recent insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 3, 2026 | Hallal David | Director | grant | 9,000 | — | — | 4 on EDGAR |
| Jun 3, 2026 | AKKARAJU SRINIVAS | Director | grant | 9,000 | — | — | 4 on EDGAR |
| Jun 3, 2026 | Ferrara Napoleone | Director | grant | 9,000 | — | — | 4 on EDGAR |
| Jun 3, 2026 | Dybbs Michael | Director | grant | 9,000 | — | — | 4 on EDGAR |
| Jun 3, 2026 | PATTERSON LEONE D | Director | grant | 9,000 | — | — | 4 on EDGAR |
| Jun 3, 2026 | Jovan-Embiricos Morana | Director | grant | 9,000 | — | — | 4 on EDGAR |
| Jun 3, 2026 | ADAMIS ANTHONY P | Director | grant | 9,000 | — | — | 4 on EDGAR |
| May 20, 2026 | AKKARAJU SRINIVAS | Director, 10% owner | purchase | 244,300 | $4.83 | $1,179,969 | 4 on EDGAR |
| Mar 19, 2026 | Feinsod Matthew | Chief Medical Officer | grant | 135,000 | — | — | 4 on EDGAR |
| Mar 20, 2026 | Hagen Brett R | Chief Accounting Officer | sale | 1,915 | $6.72 | $12,869 | 4 on EDGAR |
| Mar 19, 2026 | Gall Matthew | Chief Financial Officer | grant | 95,000 | — | — | 4 on EDGAR |
| Mar 19, 2026 | Oxtoby Andrew | See Remarks | grant | 222,000 | — | — | 4 on EDGAR |
| Dec 22, 2025 | AKKARAJU SRINIVAS | Insider | grant | 1,500,000 | $10.00 | $15,000,000 | 4 on EDGAR |
| Dec 18, 2025 | AKKARAJU SRINIVAS | Director, 10% owner | purchase | 479,847 | $10.42 | $5,000,006 | 4 on EDGAR |
Source: SEC filings via QuantConomy. Not investment advice.
Query KLRS context like a database.
These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.
More: All insider trades · How to read a Form 4 · API access